Cancer Research CommunicationsCancer BiologyPeer-reviewed journal article
Pan-cancer Analysis of Homologous Recombination Deficiency in Cell Lines
Anne E. DodsoniD, Sol ShenkeriD, Pamela SullivaniD, Sumeet U. NayakiD, Chris MiddletoniD, Michael S. McGuireiD, Edmond ChipumuroiD, Yuji MishinaiD, Erica R. TobiniD, Louise CadzowiD, Andrew A. WylieiD, Dipen P. SangurdekariD
- Citations
- 9
- FWCI
- 1.59
- Field percentile
- top 14%
Abstract
Homologous Recombination Deficiency (HRD) drives genomic instability in multiple cancer types and renders tumors vulnerable to certain DNA damaging agents such as PARP inhibitors. Thus, HRD is emerging as an attractive biomarker in oncology. A variety of in silico methods are available for predicting HRD; however, few of these methods have been applied to cell lines in a comprehensive manner. Here we utilized two of these methods, "CHORD" and "HRDsum" scores, to predict HRD for 1,332 cancer cell lines and 84 non-cancerous cell lines. Cell lines with biallelic mutations in BRCA1 or BRCA2, which encode key components of the homologous recombination pathway, showed the strongest HRD predictions, validating the two methods in cell lines. A small subset of BRCA1/2-wildtype cell lines were also classified as HRD, several of which showed evidence of epigenetic BRCA1 silencing. Similar to HRD in patient samples, HRD in cell lines was associated with p53 loss, was mutually exclusive with microsatellite instability and occurred most frequently in breast and ovarian cancer types. In addition to validating previously identified associations with HRD, we leveraged cell line-specific datasets to gain new insights into HRD and its relation to various genetic dependency and drug sensitivity profiles. We found that in cell lines, HRD was associated with sensitivity to PARP inhibition in breast cancer, but not at a pan-cancer level. By generating large-scale, pan-cancer datasets on HRD predictions in cell lines, we aim to facilitate efforts to improve our understanding of HRD and its utility as a biomarker. SIGNIFICANCE STATEMENTHomologous Recombination Deficiency (HRD) is common in cancer and can be exploited therapeutically, as it sensitizes cells to DNA damaging agents. Here we scored over 1,300 cancer cell lines for HRD using two different bioinformatic approaches, thereby enabling large-scale analyses that provide insight into the etiology and features of HRD.
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Homologous recombination deficiency in cell line libraries does not correlate with in vitro sensitivity to platinum agents or PARP inhibitors
S. Takamatsu, K. Murakami, N. Matsumura·bioRxiv·Jul 6, 2023
- Pan-cancer landscape of homologous recombination deficiency
L. Nguyen, J. Martens, … E. Cuppen·bioRxiv·Jan 13, 2020
- Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer Cohort
Majd Al Assaad, Kevin Hadi, … Juan Miguel Mosquera·medRxiv·Jun 28, 2024
- Beyond BRCA: Discovery of novel causes and consequences of homologous recombination deficiencies
Daniel James McGrail, Yang Li, … Nidhi Sahni·bioRxiv·Oct 1, 2022
- Multi-scale characterisation of homologous recombination deficiency in breast cancer
Daniel H. Jacobson, Pan Shi, … Maria Secrier·Genome MedicinePeer-reviewed·Nov 2, 2023
- DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD)
Ruolin Liu, Eugenia Roberts, … Viktor A. Adalsteinsson·Nucleic Acids ResearchPeer-reviewed·Apr 17, 2025